7.32
-0.17 (-2.27%)
| Penutupan Terdahulu | 7.49 |
| Buka | 7.63 |
| Jumlah Dagangan | 398,558 |
| Purata Dagangan (3B) | 431,388 |
| Modal Pasaran | 396,128,384 |
| Harga / Jualan (P/S) | 14.66 |
| Harga / Buku (P/B) | 10.21 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2025 - 9 May 2025 |
| Margin Operasi (TTM) | -128.01% |
| EPS Cair (TTM) | -2.28 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -6.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 152.01% |
| Nisbah Semasa (MRQ) | 2.53 |
| Aliran Tunai Operasi (OCF TTM) | -69.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -36.36 M |
| Pulangan Atas Aset (ROA TTM) | -31.03% |
| Pulangan Atas Ekuiti (ROE TTM) | -207.84% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Zevra Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -3.5 |
| Purata | 1.30 |
|
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.85% |
| % Dimiliki oleh Institusi | 62.99% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Retirement Planning Co Of New England, Inc. | 31 Dec 2024 | 514,832 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 25.00 (Canaccord Genuity, 241.53%) | Beli |
| 25.00 (Cantor Fitzgerald, 241.53%) | Beli | |
| Median | 22.00 (200.55%) | |
| Rendah | 18.00 (Citizens Capital Markets, 145.90%) | Beli |
| Purata | 22.00 (200.55%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 7.93 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Canaccord Genuity | 13 Mar 2025 | 25.00 (241.53%) | Beli | 7.94 |
| Guggenheim | 13 Mar 2025 | 22.00 (200.55%) | Beli | 7.94 |
| HC Wainwright & Co. | 13 Mar 2025 | 20.00 (173.22%) | Beli | 7.94 |
| Cantor Fitzgerald | 12 Mar 2025 | 25.00 (241.53%) | Beli | 7.92 |
| Citizens Capital Markets | 12 Mar 2025 | 18.00 (145.90%) | Beli | 7.92 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 31 Mar 2025 | Pengumuman | Zevra Therapeutics Files Preliminary Proxy |
| 11 Mar 2025 | Pengumuman | Zevra Reports Full Year 2024 and Fourth Quarter Financial Results |
| 28 Feb 2025 | Pengumuman | Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C |
| 27 Feb 2025 | Pengumuman | Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million |
| 26 Feb 2025 | Pengumuman | Zevra to Report 2024 Fourth Quarter and Full Year Financial Results |
| 24 Feb 2025 | Pengumuman | Zevra to Participate at Upcoming Investor Conferences |
| 30 Jan 2025 | Pengumuman | Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™ |
| 29 Jan 2025 | Pengumuman | Zevra Therapeutics to Participate at Upcoming Investor Conferences |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |